Immuneering News

Immuneering | 8-K/A: Current report (Amendment)

Oct 2 16:15 ET

Immuneering | 8-K: Current report

Sep 12 16:15 ET

Immuneering | 8-K: Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates - Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2024 -

Aug 6 16:16 ET

Immuneering | 8-K: Current report

Jun 13 16:16 ET

Immuneering | 8-K: Current report

May 23 16:17 ET

Immuneering | 8-K: Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates - Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors -

May 7 16:15 ET

Immuneering | DEFA14A: Others

Apr 23 16:21 ET

Immuneering | DEF 14A: Definitive information statements

Apr 23 16:17 ET

Immuneering | 8-K: Current report

Mar 14 07:08 ET

Immuneering | 8-K: Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 -

Mar 1 08:06 ET

Immuneering | 8-K: Current report

Feb 2 16:17 ET

Immuneering | 8-K: Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates -Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering's recommendation for a Phase 2 dose expected in

Nov 9, 2023 16:05 ET

Immuneering | 8-K: Current report

Aug 3, 2023 16:04 ET

Immuneering | 8-K: Current report

Jun 15, 2023 16:15 ET

Immuneering | 8-K: Current report

Jun 14, 2023 16:08 ET

Immuneering | 8-K: Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

May 4, 2023 16:03 ET

Immuneering | DEFA14A: Others

May 1, 2023 07:29 ET

Immuneering | DEF 14A: Definitive proxy statements

May 1, 2023 07:28 ET

Immuneering | 8-K: Current report

Apr 19, 2023 16:07 ET

Immuneering | 8-K: Current report

Apr 18, 2023 09:04 ET